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Abstract
Introduction: Cyclooxygenases (COXs) play important roles during inflammation. While reports on COX-2 function in
inflammation preceded those on COX-1, it is now well established that both isoforms participate in this process. During
inflammation, COX expression was reported in inflammatory leukocytes, but much less is known about their presence in tis-
sue-resident leukocytes. The aim was thus to verify the expression and activity of the COX isoforms in resident peritoneal
mast cells and macrophages during acute peritonitis. 
Materials and Methods: Zymosan peritoneal inflammation was induced in C57BL/6J mice and COX-1 and COX-2 expres-
sion was evaluated by RT-PCR (mRNA level) and immunocytochemistry (protein level). COX activity was assessed by a spe-
cific assay and prostaglandin production by ELISA. Furthermore, some mice were selectively depleted of either peritoneal
mast cells or macrophages and then COX activity was determined.
Results: The study revealed that both COXs are expressed/active at the peak of inflammation, but COX-2 predominates dur-
ing resolution. The expressions of the COXs were detectable in both populations of resident peritoneal leukocytes. In peri-
toneal macrophages both isoforms were active even during the late phases of peritonitis and the cells significantly con-
tributed to PGE2 and PGD2 synthesis. The most striking observation was that resident macrophages are critical for PGD2
production during the resolution of inflammation.
Conclusions: This study documents that both COX isoforms participate in all stages of acute inflammation and that tissue-
resident leukocytes, especially macrophages, are important sites of COX-1/COX-2 expression and prostaglandin synthesis.
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-PCR – reverse transcriptase polymerase chain reaction, SD – standard deviation, PTL – total peritoneal leukocyte.
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INTRODUCTION
An acute inflammatory response is driven by numer-
ous mediators of different origin that induce, control, or
terminate its subsequent phases from the onset of
inflammation to its resolution (Majno and Joris 2004).
Of these mediators, prostaglandins play a pivotal role at
all stages (Miller 2006; Simmons et al. 2004). Prosta-
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glandins are products of cyclooxygenase (COX) enzy-
matic activity and can be functionally divided into pro-
and anti-inflammatory (Miller 2006). The former group
includes prostaglandin (PG)E2, which promotes the
development of an inflammatory response, while the lat-
ter inhibits inflammatory activities and includes anti-
-inflammatory prostaglandins such as PGD2 and its
metabolites, cyclopentenone prostaglandins of the 
J-series (Sheibanie et al. 2007; Straus et al. 2000). 
Prostaglandins were discovered in the 1930s, and in
1971 it was shown that COX is the enzyme that cataly-
ses the biosynthesis of prostaglandins (Hamberg and
Samuelsson 1973; Vane 1971). Twenty years later it was
demonstrated that COX actually exists in two isoforms,
COX-1 and COX-2 (Fu et al. 1990; Masferrer et al.
1990; Miller 2006). From the discovery of COX-2 to the
beginning of the new millennium, the dogma was that
the constitutive COX-1 plays a role in physiological
processes, while the inducible COX-2 is involved in
inflammation, cancer, and other pathological processes
(Simmons et al. 2004; Willoughby et al. 2000). However,
the pattern of COX expression has recently been reeval-
uated upon the discovery of a constitutive expression of
COX-2 in, for example, the kidney, brain, female repro-
ductive system, and bones [for a review see (Warner and
Mitchell 2004)]. COX-1 expression was also shown to be
modulated when homeostasis becomes unbalanced; for
example, some studies on COX-1- and COX-2-deficient
mice presented evidence that COX-1 might also be
involved in inflammation (Langenbach et al. 1995;
Morham et al. 1995). 
A role for COX-1 in early vascular changes was also
shown during acute experimental peritoneal inflamma-
tion induced by zymosan, a polysaccharide component
of Saccharomyces cerevisiae (Kolaczkowska et al. 2002;
Rao et al. 1994). The study revealed that the early COX-
-1-derived prostaglandins (PGE2, PGI2) originated from
resident peritoneal leukocytes, i.e. mast cells and
macrophages (Kolaczkowska et al. 2002; Rao et al.
1994). These leukocyte populations, although often
neglected, are critical not only for the onset of peri-
toneal inflammation, but also for its later phases, includ-
ing the resolution of the inflammatory reaction
(Ajuebor et al. 1999; Kolaczkowska et al. 2007;
Kolaczkowska et al. 2002). Therefore the aim of this
study was to evaluate the involvement of tissue-resident
leukocytes in COX-1 and COX-2 activity during all
stages of zymosan peritoneal inflammation. The results
indicate that resident peritoneal mast cells and, espe-
cially, macrophages are important cellular sites of COX
activity also during its late stages.
MATERIALS AND METHODS
Mice
Male C57Bl/6 mice (6–8 weeks old, 24–27 g body
weight) were purchased from the animal-breeding unit
of the Collegium Medicum (Krakow, Poland). The mice
were kept at a room temperature of 20±2°C, and a 12-
-h:12-h light/dark cycle. The mice were fed on a com-
mercial pellet diet and tap water was available ad libi-
tum. The animals were housed 4–5 mice per cage in
polycarbonate cages on bedding containing dust-free,
microbiologically clean, soft wood granules. All in vivo
experiments were approved by the Local Ethics
Committee.
Peritonitis
Peritoneal inflammation was induced as described
previously (Doherty et al. 1985; Kolaczkowska et al.
2001b). Zymosan A (Sigma-Aldrich, St Louis, MO,
USA) was freshly prepared (2 mg/ml) in sterile 0.9 %
w/v saline and 0.5 ml was injected i.p. Animals were
killed by decapitation at the selected time points. The
peritoneal cavity was lavaged with 1 ml of saline and
after 30 sec of gentle manual massage the exudate was
retrieved and centrifuged at 400×g for 10 min. The cells
were counted with a hemocytometer following staining
with Turk’s solution (0.01% crystal violet in 3% acetic
acid) as described previously (Kolaczkowska et al.
2001b). The supernatants were frozen at –20°C prior to
analysis while the cell pellets were further treated as
described below in “COX activity assay”
Cell depletion
Resident peritoneal mast cells. Functional resident
peritoneal mast cells were removed by a single i.p. injec-
tion of compound 48/80 (Sigma-Aldrich) at a dose of 1.2
mg/kg (100 µl/mouse) 72 h before the induction of
inflammation (Das et al. 1997; Kolaczkowska et al.
2006b). Successful depletion was confirmed by a micro-
scopic analysis of safranin O-positive peritoneal leuko-
cytes [as described in (Kolaczkowska et al. 2001b); data
not shown] collected from compound-treated and
untreated mice (at time 0). The treatment lead to func-
tional depletion of over 95% of mast cells
(1.51±0.38×104 intact mast cells vs. 0.08±0.07×104
mast cells after treatment with compound 48/80). 
Resident peritoneal macrophages. To deplete resident
peritoneal macrophages, mice received i.p. injections of
100 µl of dichloromethylene diphosphonate (Cl2MDP)-
-liposomes for three consecutive days and inflammation
was induced on day 4 (Ajuebor et al. 1999;
Kolaczkowska et al. 2006b; Kolaczkowska et al. 2002).
Multilamellar liposomes containing Cl2MDP-liposomes
were prepared as described previously (van Rooijen and
Sanders 1994). Control mice were injected with either
liposomes containing phosphate buffered saline (PBS)
or sterile saline (Polskie Odczynniki Chemiczne,
Gliwice, Poland). Cl2MDP was a gift of Roche
Diagnostics GmbH, Mannheim, Germany. Successful
macrophage depletion was confirmed by an immunocy-
tochemical analysis of Mac-3-positive peritoneal cells
[as described in (Kolaczkowska et al. 2006b); data not
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shown] collected from Cl2MDP-treated and untreated
mice. Over 90% of macrophages were removed by
Cl2MDP treatment (5.98±1.32×106 intact macrophages
vs. 0.44±0.04×106 macrophages after treatment with
the liposomes).
Whenever studies on mast cell (MCx)- or
macrophage (Mφx)-depleted mice are discussed or
shown, animals with normal resident peritoneal leuko-
cyte populations are described as controls (ctr). 
Quantitative RT-PCR analysis 
The analysis was performed as described previously
(Kolaczkowska et al. 2006a; Kolaczkowska et al. 2006b).
Briefly, total RNA from cells collected from intact or
inflamed peritoneum was isolated using the
QIAshredder and RNeasy Mini Kit (QIAGEN,
Valenica, CA, USA). The amount and purity of the total
RNA was determined by spectrophotometry
(GENESYS 10 UV; Thermo Electron Corporation,
Waltham, MA, USA) at 260 nm. RNA was translated
into single-stranded cDNA using the Superscript
cDNASynthesis kit (Invitrogen, Carlsbad, CA, USA)
and random hexamers (Amersham Biosciences,
Piscataway, NJ, USA). Relative gene expression levels
were determined using real-time PCR TaqMan technol-
ogy (GeneAmp 5700 Sequence Detection System;
Applied Biosystems, Foster City, CA, USA) and SYBR
green (Eurogentec, Liege, Belgium) incorporation. The
mouse hypoxanthine phosphoribosyltransferase (HPRT)
gene served as an internal standard. The following





Immunocytochemical detection of COX-1 and COX-2
Cytospins containing 5×105 peritoneal leukocytes
were prepared on slides coated with silicone
(Sigmacote®, Sigma-Aldrich) by centrifugation (5 min
at 1500 rpm; Hettich Universal, Tuttlingen, Germany).
The cytospin preparations were immediately fixed with
a methanol:acetone mixture (1:1) and stored at
–20°C until analysis. The immunocytochemical proce-
dure was performed as described in detail previously
(Kolaczkowska et al. 2007). The antibodies used were:
for COX-1, primary rabbit anti-mouse anti-COX-1 puri-
fied antibody (Cayman Chemical, Ann Arbor, MI,
USA) diluted 1:500 and secondary goat anti-rabbit
immunoglobulin G (IgG) peroxidase-conjugated anti-
body (Sigma-Aldrich) diluted 1:1000, and for COX-2,
purified mouse anti-mouse anti-COX-2 (BD
Biosciences, San Diego, CA, USA; 1:500) and biotiny-
lated rat anti-mouse IgG (BD Biosciences; 1:400) fol-
lowed by streptavidin-peroxidase complex (BD
Biosciences). In both cases the products of the reaction
were visualized with 3’,3’-diaminobenzidine tetrahy-
drochloride (DAB; ICN Int., Basel, Switzerland) and
the cells were further counterstained with Harris hema-
toxyline (Stamar, D¹browa Górnicza, Poland) to facili-
tate identification of positive and negative cells.
Negative controls were incubated with neither primary
nor secondary antibodies. The cytospine preparations
were examined under a light microscope (400×) and
photographed at a magnification of 1000× (Coolpix
4500, Nikon, Tokyo, Japan). The percentages of COX-
-1- and COX-2-positive cells were counted with an eye-
piece graticule (20×20). For each time point at least
three cytospins were stained and analyzed, of which
three to four fields were counted. The percentages of
COX-1+ and COX-2+ cells were recalculated per total
peritoneal leukocyte (PTL) numbers [a pattern of PTL
kinetics was published previously: (Kolaczkowska et al.
2008a; Kolaczkowska et al. 2001b) and are shown here
as absolute COX-1- or -2-positive cell numbers in the
peritoneum].
COX activity assay
First the cell pellets were homogenized. For this they
were resuspended in 50 µl of cold buffer (0.1 M Tris-
-HCl, pH 7.8, containing 1 mM EDTA) and centrifuged
at 10,000×g for 15 min at 4°C. The supernatants were
collected and frozen at –80°C prior to assay. COX activ-
ity was then measured using a commercial COX Activity
Assay (Cayman Chemical) that measures the peroxidase
activity of COX. The assay was performed according to
manufacturer’s instructions. Briefly, the peroxidase
activity was assayed colorimetrically by monitoring the
appearance of oxidized N,N,N’,N’-tetramethyl-p-
-phenylenediamine (TMPD) at 590 nm. The activities of
COX-1 and COX-2 were differentiated using the iso-
form-specific inhibitors DuP-697 (selective COX-2
inhibitor) and SC-560 (selective COX-1 inhibitor)
according to the manufacturer’s instructions. This kit
also includes purified ovine COX-1 as a positive control
and its activity was inhibited by SC-560, but not by DuP-
-697. COX activity is expressed as the rate of oxidation
of TMPD in units of nmol/min/mg protein.
Determination of PGE2 and PDE2 concentration 
by ELISA
PGE2 and PDE2 levels were estimated by ELISA kits
from Cayman Chemical according to the manufactur-
er’s instructions.
Statistical analysis
All values are reported as the mean ±SD. Kinetic
changes in each parameter were analyzed by one-way
analysis of variance (ANOVA) followed by post hoc
Tukey’s test to compare the values recorded at the indi-
vidual time points with those at time 0 (in intact ani-
mals). Differences between control (ctr) and Mφx or
MCx animals were analyzed by Student’s t-test.
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Differences were considered statistically significant at
p≤0.05.
RESULTS
Kinetics of COX-1 and COX-2 mRNA changes 
during zymosan peritonitis
Upon injection of zymosan, the levels of mRNA
encoding COX-1 dropped (Fig. 1A). During the next
hours the amount of COX-1 transcript fluctuated slight-
ly (not significantly) and stayed at a low level until the
24th h of inflammation (Fig. 1A). In contrast, COX-2
mRNA levels were negligible in intact mice, but dra-
matically increased already 2 h after zymosan injection
and stayed at an equally high level for the next 4 h (Fig.
1A). At 8 h of inflammation, COX-2 mRNA levels
dropped radically and at 24 h returned to the levels
detected in intact mice (Fig. 1A). The COX-1 mRNA
levels were significantly higher than those of COX-2 in
the untreated mice, but the opposite phenomenon was
observed at 6 h of peritonitis.
Changes in COX-1+ and COX-2+ peritoneal 
cell numbers during zymosan peritonitis
Almost all leukocytes present in the peritoneum of
the intact mice were COX-1 positive. At 4 h of inflam-
mation the COX-1+ counts increased, reaching maximal
numbers at 8 h, and then started to fall, reaching control
levels at 24 h (Fig. 1B). In contrast to COX-1, only some
peritoneal leukocytes present in the peritoneum of
intact mice stained positively for COX-2. From the 4th
h of peritonitis, the numbers of COX-2+ leukocytes
started to increase and the highest COX-2+ counts were
detected at 8 h. By 24 h of inflammation they had
returned to the levels detected in the intact animals
(Fig. 1B). At 4 and 8 h of peritonitis there were notice-
ably more COX-1+ than COX-2+ leukocytes, while this
difference was not significant at 6 h of peritonitis as
there was considerable variation in the COX-1 signal
among the mice.
Examples of immunocytochemical staining of peri-
toneal leukocytes for COX-1 and COX-2 are presented
in Fig. 2. The staining revealed that cells carrying COX-
1 were much more numerous than those containing
COX-2 (left vs. right column). Moreover, COX-1+
leukocytes were also frequent in the zymosan-untreated
mice (time 0), in contrast to the few COX-2+ cells (Fig.
2). The percentage of COX-positive cells recorded by
immunocytochemical staining (Fig. 2) was subsequently
recalculated per PTL number and the results are pre-
sented in Fig. 1B. Some indirect conclusions on the cel-
lular sources in which COX-1 and COX-2 expression
take place can be based on the data presented in Fig. 1B.
In particular one can observe that almost all leukocytes
expressed COX-1 protein under either physiological or
inflammatory conditions. Moreover, expression of COX-
1 and COX-2 might occur within the same cells, as the
collective numbers of COX-1+ and COX-2+ cells are
higher than those of PTLs (e.g. at 6–8 h). Our previous
studies showed that at 6 and 24 h of zymosan peritonitis,
each COX isoform is expressed equally in neutrophils
and macrophages present in the peritoneum, without any
cell-type restrictions (Kolaczkowska et al. 2009).
Kinetic changes in COX-1 and -2 activities 
during zymosan peritonitis
The activity of both COX isoforms was low in the
untreated mice and increased upon zymosan injection
(Fig. 1C). COX-1 activity enhanced during inflamma-
tion, reaching its highest values at 6 hrs, and then start-
Fig. 1. Kinetic changes in COX expression and activity at the tran-
script and protein levels during zymosan peritonitis in mice. Mice
were injected i.p. with zymosan and decapitated at the selected
time points; some animals were left untreated (controls, time 0).
Relative COX-1 and COX-2 mRNA expression was estimated in
pellets of peritoneal leukocytes (A). Peritoneal lavages were used
to estimate (B) the numbers of COX-1+ and COX-2+ peritoneal
cells among all leukocytes present in the peritoneum and (C) eval-
uation of COX isoforms in peritoneal leukocytes. Upper case let-
ters are used for COX-1 and lower case for COX-2. All results are
shown as the mean ±SD in groups of 3–5 mice. Mean values not
sharing letters are statistically significantly different according to
ANOVA (p<0.05). Some differences between COX-1 and COX-2
mRNA expression are statistically significant at 0.01≤p≤0.05 (*),
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ed to drop (Fig. 1C). COX-2 activity gradually increased
in the course of zymosan peritoneal inflammation,
reaching maximal values at 8 h (Fig. 1C). At 24 h of peri-
tonitis, both COX activities decreased; however, this
effect was significantly stronger in the case of COX-1
than COX-2 (Fig. 1C). 
Levels of PGE2 and PGD2 during zymosan peritonitis
Only negligible levels of PGE2 and PGD2 were
detected in the peritoneal fluid of the intact mice (Fig.
3A, B). The levels of PGE2 increased upon zymosan in
vivo stimulation and reached maximal values between 2
and 4 h (Fig. 3A). From the 6th h of peritonitis the
PGE2 levels started to decrease and at 8 h they were
already at the basal levels (Fig. 3A). PGD2 was already
present in the peritoneal exudate at 2 h of inflammation
and reached its highest values at 24 h of inflammation
(Fig. 3B). 
Dependence of COX-1 and COX-2 activity 
on the presence of resident peritoneal macrophages
and mast cells during zymosan peritonitis
The absence of either resident peritoneal
macrophages or mast cells decreased COX-1 activity at
every investigated time point (Fig. 4A). COX-2 activity
was affected by the removal of either resident peritoneal
population only at 6 h of inflammation, whereas in
untreated mice and at 24 h of peritonitis only a lack of
macrophages reduced it (Fig. 4B).
Impact of resident peritoneal macrophages and mast cells
on PGE2 and PGD2 synthesis during zymosan peritonitis
Lack of either population weakened PGE2 produc-
tion in intact mice, while at 6 h of inflammation only
a lack of peritoneal macrophages significantly decreased
its production (Fig. 5A). At 24 h of peritonitis, no sig-
nificant changes in PGE2 were observed upon removal
of any resident leukocyte population. In intact animals,
PGD2 synthesis was affected by a lack of functional mast
cells, but not macrophages (Fig. 5B). In contrast, at 6
and 24 h of inflammation, significantly reduced PGD2
production was observed only in the absence of peri-
toneal macrophages (Fig. 5B).
DISCUSSION
This study was performed on an experimental model
of acute inflammation induced by stimulation of the
peritoneum with zymosan. The model includes all the
well-known hallmarks of acute inflammation: the onset
of inflammation accompanied by an increase in vascular
permeability (<1 h), the peak of inflammation reflected
by neutrophil infiltration into the peritoneum (with
Fig. 2. Immunocytochemical detection of COX-1 and COX-2
expression in peritoneal leukocytes during zymosan peritonitis.
Mice were injected i.p. with zymosan and decapitated at the select-
ed time points; some animals were left untreated (intact, time 0).
Examples of peritoneal leukocytes (PTLs) positive for COX-1 and







Fig. 3. Kinetic changes in prostaglandin production during
zymosan peritonitis in mice. Mice were injected i.p with zymosan
and decapitated at the selected time points; some animals were
left untreated (controls, time 0). Content of PGE2 (A) and PGD2
(B) in the peritoneal exudate was monitored. All results are shown
as the mean ±SD in groups of 3–5 mice. Mean values not sharing
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highest leukocyte numbers at 6 h) and the release of
numerous pro-inflammatory mediators, and finally the
resolution of inflammation (Ajuebor et al. 1999;
Doherty et al. 1985; Kolaczkowska et al. 2006a;
Kolaczkowska et al. 2001a; Kolaczkowska et al. 2007;
Kolaczkowska et al. 2006b; Kolaczkowska et al. 2001b;
Kolaczkowska et al. 2002). The last process is accompa-
nied by inflammatory macrophage inflow (after 24 h)
and anti-inflammatory mediator synthesis. 
The current report shows the whole sequence of
events, from changes in COX mRNA content to the
expression of the protein in leukocytes and finally COX
activity evaluated by two different approaches. The
study revealed that the expression of COX-1 mRNA
decreases upon zymosan injection. This could be
explained by an enormous demand for COX-1 protein
resulting in the translation of the majority of its tran-
script pool. In fact, the increasing expression of COX-1
protein in leukocytes in the course of zymosan peritoni-
tis as well as the very intensive production of
prostaglandins seem to confirm this supposition. In con-
trast, COX-2 transcript increased after zymosan admin-
istration. Similar observation was described previously
with semi-quantitative PCR analysis that revealed the
appearance of a weak COX-2 mRNA signal already at
30 min of zymosan peritonitis (Kolaczkowska et al.
2002), but here we show that the transcript levels rise
further. The numbers of cells expressing COX-1 and
COX-2 also rose upon zymosan injection and this corre-
lated with the increasing activity of both isoforms.
Interestingly, we indirectly detected that COX-1 and
COX-2 expression occurred in the same leukocytes at
the peak of inflammation. These findings confirm that
not only COX-2, but also COX-1 plays an important
role in inflammation and not only in physiological
processes. The activity of the COXs was evaluated by
their ability to catalyze the synthesis of their products: ex
vivo of oxidized TMPD by its peroxidase activity (see
“COX activity assay”) and in vivo by the production of
prostaglandins E2 and D2. During the course of zymosan
peritonitis, both COX activities were enhanced and
even 24 h post-injection both were significantly elevat-
ed; however, COX-2 activity was stronger. This implies
Fig. 4. Effects of peritoneal mast cell and macrophage depletion
on cyclooxygenase activity during zymosan peritonitis. All animals
were injected i.p with zymosan and decapitated at the selected
time points. Before the induction of peritonitis, some mice were
depleted of either peritoneal macrophages (Mφx) or mast cells
(MCx); ctr – control mice with normal peritoneal cell populations.
COX-1 (A) and COX-2 (B) activity in peritoneal leukocytes was
monitored. All results are shown as the mean ±SD in groups of 3–5
mice. Some differences are statistically significant at 0.01≤p≤0.05























































Fig. 5. Effects of peritoneal mast cell and macrophage depletion
on prostaglandin production during zymosan peritonitis. All ani-
mals were injected i.p. with zymosan and decapitated at the select-
ed time points. Before the induction of peritonitis, some mice
were depleted of either peritoneal macrophages (Mφx) or mast
cells (MCx); ctr – control mice with normal peritoneal cell popu-
lations. PGE2 (A) and PGD2 (B) content in the peritoneal exudate
was monitored. All results are shown as the mean ±SD in groups
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that the COXs are also involved in the resolution of
peritonitis. 
The second approach used to evaluate COX activity
was the measurement of prostaglandin production in
samples collected in situ at the inflammatory focus. The
production of prostaglandins in this model has been the
subject of numerous investigations. It was shown that
PGE2 and PGI2 are produced very intensively within the
first 45 min of zymosan application and, while the syn-
thesis of the latter drops within half an hour, PGE2 is
also synthesized at later time points (Doherty et al.
1985; Kolaczkowska et al. 2002; Rao et al. 1994). In con-
trast, to the best of our knowledge the production of
anti-inflammatory PGD2 (precursor of the prosta-
glandin J series) has not yet been investigated in this
model. In the current study, kinetic analyses revealed
that PGE2 is produced in large amounts during the peak
of inflammation, while PGD2 is synthesized during both
the peak and the resolution phases of peritonitis. Thus
COX activity, especially that of COX-2, during the late
stages of peritonitis might be related to the high pro-
duction of PGD2 at this time. These results correspond
with those of studies on another model of acute inflam-
mation, namely rat carrageenan-induced pleurisy
(Gilroy et al. 1999; Gilroy et al. 1998). 
The major goal of the current investigations was to
verify the involvement of resident peritoneal leukocytes
in COX activity and prostaglandin synthesis during
zymosan peritoneal inflammation. The murine peri-
toneum contains macrophages, lymphocytes, and mast
cells, with highest numbers of the first and lowest of the
mast cells (Tchougounova et al. 2005). However, lym-
phocytes do not participate in zymosan peritonitis
(Kolaczkowska et al. 2008b). The role of tissue-resident
leukocytes was disregarded for a long time, but the cells
play an important role not only in the initiation of
inflammation, but also at later stages of the reaction.
For example, at the onset and the peak of zymosan peri-
toneal inflammation, resident peritoneal macrophages
and mast cells produce chemokines (Ajuebor et al.
1999) and MMP-9 (Kolaczkowska et al. 2007) that are
critical for neutrophil infiltration into the peritoneum.
The current study revealed that a lack of mast cells
decreased COX activity (COX-1 at 6 and 24 h and
COX-2 at 6 h), but it had no significant impact on PGE2
and PGD2 production at those time points. However, it
cannot be excluded that the decrease in COX activity in
mice deprived of functional mast cells might be linked to
the decreased neutrophil infiltration observed in these
animals (Ajuebor et al. 1999) and not due to the high
COX activity in resident mast cells. Nevertheless, as we
showed in the current study, the basic COX-1 activity
present in untreated peritoneal leukocytes can undoubt-
edly be attributed to mast cells. Furthermore, mast cells
co-synthesize PGE2 and exclusively produce PGD2 in
intact mice. This is not surprising, as PGD2 is the major
COX product of mast cells (Ueno et al. 2008). 
Moreover, the study showed that resident peri-
toneal macrophages carry out both COX activities at
every stage of zymosan peritonitis. At the peak of
inflammation, COX-1 and COX-2 of macrophage ori-
gin contribute to PGE2 synthesis and at the time of res-
olution also to PGD2 synthesis. In contrast to the
removal of mast cells, it was shown that the elimination
of resident peritoneal macrophages increases neu-
trophil accumulation at later stages of peritonitis and
this was explained by the lack of production of anti-
inflammatory interleukin (IL)-10 synthesized by those
cells (Ajuebor et al. 1999; Kolaczkowska et al. 2007).
Therefore the down-regulation of COX activities and
prostaglandin synthesis can indeed be attributed to the
lack of resident peritoneal macrophages and thus indi-
cates that it occurs in those cells during the whole
course of peritonitis. Moreover, the current study
shows that not only the lack of IL-10, but most proba-
bly also of PGD2 might be responsible for the pro-
longed presence of neutrophils in the peritoneum of
mice depleted of resident peritoneal macrophages. In
fact, the detection of such a strong involvement of resi-
dent peritoneal macrophages in the synthesis of PGD2
at 24 h of inflammation is the most striking discovery. It
should be kept in mind that at this time point, inflam-
matory macrophages still arrive at the inflammatory
focus (Kolaczkowska et al. 2001b) and it was assumed
that these are the cells responsible for the production
of anti-inflammatory prostaglandins. 
In conclusion, we showed that fluctuations in the
expression and activity of both COX isoforms accompa-
ny the course of acute inflammation. Most importantly,
we showed that resident peritoneal mast cells and, espe-
cially, macrophages are important leukocyte types in
which COX activity occurs. This COX activity is not lim-
ited to the early inflammatory stages, but is also critical
for PGD2 production at the late resolution phase of
inflammation. 
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